HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials by Gennari Alessandra, Sormani Maria Pia, Pronzato Paolo, Puntoni Matteo, Colozza Mariantonietta, Pfeffer Ulrich, Bruzzi Paolo in Journal of the National Cancer Institute (2008).

[PMID: 18159072] PubMed


Adjuvant chemotherapy with anthracyclines improves disease-free and overall survival compared with non-anthracycline-based adjuvant chemotherapy regimens in the treatment of early breast cancer. The role of HER2 status as a marker of anthracycline responsiveness has been explored by subset analyses within randomized clinical trials, with inconsistent results. We performed a pooled analysis of the interaction between HER2 status and the efficacy of adjuvant anthracyclines based on the published subset data.

[ hide abstract ]

Discussed In Paper


Dosing Information

No dosing information annotated.